Infinity Pharmaceuticals (NASDAQ:INFI) issued its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.04, AR Network reports.
Several analysts have recently commented on the stock. Analysts at UBS AG downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, October 23rd. On a related note, analysts at William Blair initiated coverage on shares of Infinity Pharmaceuticals in a research note to investors on Monday, September 23rd. They set a “market perform” rating and a $21.00 price target on the stock. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Infinity Pharmaceuticals from $20.00 to $22.00 in a research note to investors on Wednesday, September 18th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $32.25.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) remained flat at $11.97 during trading on Thursday. The stock had a trading volume of 1,506,191 shares. Infinity Pharmaceuticals has a 52-week low of $11.94 and a 52-week high of $50.51. The stock has a 50-day moving average of $15.56 and a 200-day moving average of $21.00. The company’s market cap is $574.3 million.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.